Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
March 25, 2021

Coronavirus company news summary – Hong Kong and Macao suspend BioNTech Covid-19 vaccination after packaging flaw – Clover and Dynavax dose first patients in Phase II/III SPECTRA vaccine trial

By Chris Lo

Fosun Pharma, BioNTech’s partner in the development and distribution of the Comirnaty Covid-19 vaccine in greater China, have notified Hong Kong and Macao of a packaging flaw in batch 210102 of the vaccine. Shares of China’s Shanghai Fosun Pharmaceutical Group fell 5% after the cities suspended BioNTech vaccinations as a precautionary measure. The cities stated that the German vaccine maker and Fosun are currently investigating the cause of the vial cap defect.

Clover Biopharmaceuticals and Dynavax Technologies have dosed the first participants in the global Phase II/III SPECTRA trial to test the safety, efficacy, and immunogenicity of Clover’s protein-based S-Trimer Covid-19 vaccine candidate adjuvanted with Dynavax’s CpG 1018 plus alum. The double-blinded, randomised, controlled study of the Covid-19 vaccine will see the vaccine administered in two doses, given 21 days apart.

Health Canada has issued a guidance for updating the label or product monograph for the Astrazeneca and Covishield Covid-19 vaccines to provide information on rare reports of blood clots linked to low levels of blood platelets following immunisation with the AstraZeneca vaccine. The agency has also issued guidance for various healthcare professionals and vaccine recipients on monitoring the potential symptoms of the vaccine.

Related Companies

Content from our partners
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU